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PolyketidesA B S T R A C T
Objective/background: According to estimates by the World Health Organization, there were
9.6 million new tuberculosis (TB) cases in 2014: 5.4 million among men, 3.2 million among
women, and 1.0 million among children. There were also 1.5 million TB deaths. Although
there are potent anti-TB molecules, the misuse of these drugs in addition to inconsistent
or partial treatment have led to the development of multidrug-resistant TB and extensively
drug-resistant TB. It is established that plants harbor microorganisms, collectively known
as endophytes, which also produce metabolites. Exploring the as-yet untapped natural
products from the endophytes increases the chances of finding novel and active com-
pounds. The present study was aimed to investigate the antimycobacterial activity of the
crude extract and compounds isolated from Penicillium sp. endophyte associated with Gar-
cinia nobilis against Mycobacterium smegmatis.
Methods: Liquid culture obtained from the fermentation of Penicillium sp. was extracted
using ethylacetate and the liquid chromatography–mass spectrometry monitored fraction-
ation of crude extracts yielded six compounds. Their structures were elucidated with spec-
troscopic analyses including two-dimensional nuclear magnetic resonance, high resolution
mass spectrometry by dereplication using Antibase, and by comparison to literature data.
All compounds and the crude extract from the liquid medium were evaluated for their
antimycobacterial activity against M. smegmatis.
Results: In this study, the activity of penialidins A–C (1–3), citromycetin (4), p-hydroxy phe-
nyl glyoxalaldoxime (5), and Brefeldin A (6) were tested against nonpathogenic M. smegma-
tis. Penialidin C was the most active compound with a minimum inhibitory concentration
of 15.6 lg/mL.
Conclusion: Isolated compounds from Penicillium sp. harbored in G. nobilis exhibited promis-
ing antimycobacterial activity against M. smegmatis thus supporting the immensity of the
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 1 9 2 –1 9 6 193potential of antimycobacterial drug discovery from endophytes from medicinal plants.
Penialidin C could further be investigated for antimycobacterial drug development.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB) is currently a major public health problem
due to the advent of multidrug-resistant (MDR) forms of
bacilli as well as human immunodeficiency virus epidemics.
Global efforts are underway to eradicate TB using new drugs
with new modes of action, higher activity, and fewer side
effects. For this reason, unexplored new sources and previ-
ously explored sources were examined and around 353
antimycobacterial compounds [1] have been previously
reported. To develop drugs from these new sources, addi-
tional work is required for preclinical and clinical evaluation.
In 2014, there were an estimated 9.6 million new TB cases: 5.4
million among men, 3.2 million among women, and 1.0 mil-
lion among children. Also, there were 1.5 million TB deaths
[2,3]. A potent antitubercular drug rifampicin (RMP), which
was introduced 50 years ago, is still currently being used for
treatment in combination with isoniazid (INH), ethambutol
(EMB), and pyrazinamide (PZA) as a multidrug regimen for a
period of at least 6 months. The misuse of these drugs in
addition to inconsistent or partial treatment has led to the
development of MDR-TB and extensively drug-resistant TB.
The resistant strains coupled with drug hepatotoxicity and
lengthy therapy paved the way for a TB therapeutic crisis
[4–7]. This situation presently acts as a serious challenge to
the health care system. Thus, it becomes necessary to priori-
tize the search for new antimycobacterial agents worldwide
[8,9]. As part of our research activities in discovering potent
anti-TB compounds [10] and based on our previous investiga-
tion on the antibacterial activity of some compounds [11], we
further our investigation with the determination of the activ-
ities of metabolites produced by endophytes on mycobacteria,
subject of this report.
Materials and methods
General experimental procedures
The high resolution mass spectra were obtained with an LTQ-
Orbitrap Spectrometer (Thermo Fisher, Waltham, MA, USA)
equipped with a HESI-II source. The spectrometer was oper-
ated in positive mode (1 spectrum/s; mass range: 100–1000)
with nominal mass resolving power of 60,000 at m/z 400 with
a scan rate of 1 Hz) with automatic gain control to provide
high-accuracy mass measurements within 2 ppm deviation
using an internal standard, bis (2-ethylhexyl) phthalate: m/
z = 391.28428. The spectrometer was attached with an Agilent
(Santa Clara, CA, USA) 1200 High Performance Liquid Chro-
matography (HPLC) system consisting of a LC-pump, photodi-
ode array detector (k = 260 nm), auto sampler (injection
volume 5 lL), and column oven (30 C). The following param-
eters were used for experiments: spray voltage 5 kV, capillarytemperature 260 C, and tube lens 70 V. Nitrogen was used as
a sheath gas (50 arbitrary units) and auxiliary gas (5 arbitrary
units). Helium served as the collision gas. The high resolution
mass spectra of compounds was performed on a preparative
HPLC using a Nucleodur C18 gravity column (50 mm  2 mm,
1.8-lm particle size) with a H2O (+0.1% HCOOH; A)/acetoni-
trile (+0.1% HCOOH; B) gradient (flow rate 350 lL/min). Sam-
ples were analyzed using a gradient program as follows:
95% A isocratic for 10 min, linear gradient to 100% B over
14 min, after 100% B isocratic for 4 min, the system returned
to its initial condition (95% A) within 0.5 min, and was equili-
brated for 4.5 min (flow rate 350 lL/min). The purification was
carried out using a preparative HPLC run for 20 min on a Gil-
son apparatus with UV detection at 220 nm using a Nucleodur
C18 Isis column (Macherey–Nagel, Du¨ren, Germany), 5 lm
(250 mm  16 mm) with a H2O (A)/CH3OH (B) gradient (flow
rate 4 mL/min). Samples were separated using a gradient pro-
gram as follows: 60% A isocratic for 2 min, linear gradient to
100% B over 18 min, after 100% B isocratic for 5 min, the sys-
tem returned to its initial condition (60% A) within 0.5 min,
and was equilibrated for 4.5 min. Silica gel (Merck, Kenil-
worth, NJ, USA [0.063–0.200 mm]) was used for column chro-
matography. The nuclear magnetic resonance (NMR) spectra
were recorded on a Bruker DRX-500 MHz, Bruker BioSpin, 34
RUE DE L INDUSTRIE. 67160, Wissembourg, France,
spectrometer.
Sampling of Garcinia nobilis
Leaves of G. nobilis were collected in Mount Etinde in the
Southwest Region of Cameroon. The plant material was iden-
tified by Mr. Victor Nana, botanist at the Cameroon National
Herbarium (Yaounde´, Cameroon) under a voucher specimen
(50779/HNC/Cam/Mt Zamangoue´).
Isolation and identification of the endophytic fungus
The healthy leaf was first cleaned by washing it several times
under running tap water and then cut into small slices, fol-
lowed by successive surface sterilization in 70% ethanol and
NaOCl (6–14% active chlorine) for 2 min and finally with ster-
ile distilled water for two to three times. Plant material was
then dried in between the folds of sterile filter papers and
deposited on a petri dish containing potato dextrose agar
medium (20 g of potato, 20 g of dextrose, and 15 g of agar in
1 L of H2O [supplemented with 100 mg/L of chloramphenicol
to suppress bacterial growth]) and incubated at 25 C until
the growth of endophytic fungi was discerned. Hyphal tips
originating from plant segments were transferred to potato
dextrose agar. Each fungal isolate was checked for purity
and transferred to the new medium using the hyphal tip
method. One of the isolates, CAM64, was selected for further
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phy–mass spectrometry profile of its crude extract from small
scale fermentation. The fungus was identified as Penicillium
sp., as previously described [11].
Fermentation, extraction, and isolation of secondary
metabolites
Fermentation and extraction from potato dextrose broth
medium were described during our previous investigation of
this fungus. Compounds tested herein, penialidins (A–C)
and citromycetin (1–4; Fig. 1) were obtained as we previously
reported for their isolation and characterization from potato
dextrose broth medium of the investigated fungus [11].
Antimycobacterial assay
The activities were screened using the Alamar Blue method as
previously described. A modified twofold serial dilution of
extract/compound in 96-well microtiter plates was used to
detect antimycobacterial activity [12,13]. Isolated compounds
were serially diluted (100 lL) with albumin dextrose saline
supplemented with Middlebrook 7H9 broth in the wells of a
microtiter plate before mycobacterial culture (100 lL) was
added to each well. The combined anti-TB drugs RMP
150 mg, INH 75 mg, EMB 275 mg, and pyrazinamide 400 mg
was used as a positive control, and media controls were
included. Various dilutions were tested in triplicate and the
entire experiment was repeated.
The microplates were sealed with parafilm and placed in
an environmental shaker; this was incubated at 37 C for
48 h. Minimal inhibitory concentration (MIC) values were






























Fig. 1 – Structures of penialidin A–C (1–3), citromycetin (4), p-reaction after the addition of resazurin generally occurred
after a 2-h incubation period. MIC values were read as those
concentrations where a pronounced change of color forma-
tion was noticed (from blue to orange).
Results
From the fermentation of this fungus, the crude extract (3.2 g)
was first partitioned with cyclohexane to remove fatty mate-
rial. The resulted polar fraction (1.8 g) was then subjected to
column chromatography using Sephadex LH-20 to yield four
main fractions (Fr1–Fr4) after thin layer chromatography
monitoring. Fractions Fr2 (96 mg) and Fr3 (105 mg) were puri-
fied by preparative HPLC eluting with a gradient of MeOHH2-
O+ 0.1%TFA to yield p-hydroxy-phenyl glyoxalaldoxime (5)
C8H8O3N (4.6 mg, tR = 6.73 min, HRESIMS at 166.05022 [M
+H]+: (calculated 166.05042), and Brefeldin A (6) C16H24O4
(3.5 mg, tR = 12.06 min, HRESIMS at 281.17957 [M+H]
+: (calcu-
lated 281.17528). Their structures (Fig. 1) were determined
from their high resolution mass spectrometry combined to
1H and 13C NMR, by introducing these data into Antibase
[14] and finally confirmed by two-dimensional NMR spectra.
The chemical shifts were in agreement with those reported
in the literature [15].1H NMR and 13C NMR data of compounds 5 and 6
p-Hydroxy-phenyl glyoxalaldoxime (5): 1H NMR (500 MHz,
CD3OD, d [ppm], J [Hz]): d 8.05 (1H, d, 8.8, H-2/20), 6.87 (2H, m,
H-3/30), 8.04 (1H, s, H-6), and 13C NMR (500 MHz, CD3OD,d
[ppm]): d 138.9 (C-1), 147.6 (C-2/20), 115.1 (C-3/30), 163.2 (C-4),

































hydroxy-phenyl-glyoxalaldoxime (5), and Brefeldin A (6).
Table 1 – Antimycobacterial activity of compounds 1–6 compared with a standard reference.
Test samples MIC (lg/mL)
Crude extract (liquid medium) 62.5
1. Penialidin A 62.5
2. Penialidin B 62.5
3. Penialidin C 15.6
4. Citromycetin 31.2
5. p-Hydroxy-phenyl-glyoxalaldoxime 62.5
6. Brefeldin A 250
RMP/INH/EMB/PZA 0.62
Note. All values were derived from experiments done in triplicates. EMB = ethambutol; INH = isoniazid; PZA = pyrazinamide; RMP = rifampicin.
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7.47 (1H, dd, 15.6, 3.1, H-2), 5.85 (1H, dd, 15.6, 1.9, H-3), 4.06
(1H, dt, 4.6, 2.5, H-4), 1.86 (1H, m, H-5), 2.04 (1H, m, H-6a),
1.83 (1H, m, H-6b), 4.24 (1H, m, H-7), 2.16 (1H, m, H-8a), 1.47
(1H, m, H-8b), 2.40 (1H, m, H-9), 5.29 (1H, m, H-10), 5.76 (1H,
m, H-11), 2.04 (1H, m, H-12a), 1.88 (1H, m, H-12b), 0.95 (2H,
m, H-13), 1.79 (1H, m, H-14a), 1.61 (1H, m, H-14b), 4.82 (1H,
d, 1.1, H-15), 1.27 (3H, d, 6.3, H-16), and 13C NMR (500 MHz,
CD3OD,d [ppm]): d 167.3 (C-1), 154.1 (C-2), 116.8 (C-3), 75.2 (C-
4), 52.1 (C-5), 40.5 (C-6), 71.9 (C-7), 43.1 (C-8), 44.0 (C-9), 137.0
(C-10), 130.9 (C-11), 31.9 (C-12), 10.5 (C-13), 34.0 (C-14), 72.1
(C-15), and 20.0 (C-16).
All compounds and the crude extract from the liquid med-
ium were tested for their antimycobacterial activities and
compared with the positive control. Results are provided in
Table 1. Penialidin C was the most active compound with a
MIC of 15.6 lg/mL, followed by citromycetin with a MIC of
31.2 lg/mL and RMP/INH/EMB/PZA used as a reference drug
in the assay having a MIC value of 0.62 lg/mL.
Discussion
Our study showed that penialidin C, isolated from the endo-
phyte Penicillium sp. harbored by G. nobilis, has antimycobacte-
rial activity.
G. nobilis is found in the Southwest Region of Cameroon
and is known to be a rich source of bioactive xanthones
[16,17]. Similar to the small peptides, polyketides constitute
a large proportion of industrial antibiotics. More than 300
novel antitubercular agents were identified and characterized
from biological sources between 2003 and 2005, while there
were a further 450 novel entities identified from 2006 to
2009. Furthermore, there have been 28 novel compounds iso-
lated from microbial sources between 2008 and 2012. Of
these, 11 were polyketides or polyketide derivatives [18].
WHO declared TB as global emergency because of the
increase of TB cases with the advent of human immunodefi-
ciency virus/AIDS infection and the emergence of MDR and
extensively drug-resistant TB strains [19]. No new antimy-
cobacterial has been introduced in the past 30 years; hence,
there is an urgent need to develop novel, safe, effective, and
affordable antitubercular agents. There has been a renewed
interest in microbes as a source of novel bioactive compounds
in the past decade. Thus, endophytes have been investigated
for various pharmacological effects including antimycobacte-
rial activity [20,21]. Medicinal plants are recognized asrepository for fungal endophytes with metabolites containing
novel molecular structures and biologically active compounds
against various human pathogenic diseases for potential use
in modern medicine [22]. A number of endophytic fungi from
some Garcinia species have been found to produce new
antitubercular secondary metabolites [23,24].
The observed activities of these compounds support the
immensity of the potential of antimycobacterial drug discov-
ery from endophytes from medicinal plants. Penialidin C was
identified in our study as having antimycobacterial activity
and could be further investigated for its development as an
anti-TB drug.Conflicts of interest
We declare that we have no conflicts of interest.
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